In juvenile animal studies Rabeprazole sodium was administered orally to rats for up to 5 weeks and to dogs for up to 13 weeks, each commencing on Day 7 post-partum and followed by a 13-week recovery period. Most patients heal within four weeks.Rabeprazole Sodium Delayed-Release Tablets, in combination with amoxicillin and clarithromycin as a three drug regimen, are indicated for the treatment of patients with In patients who fail therapy, susceptibility testing should be done. In most patients, treatment of hypomagnesemia required magnesium replacement and discontinuation of the PPI.For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), healthcare professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose; The following serious adverse reactions are described below and elsewhere in labeling:Because clinical trials are conducted under varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.The data described below reflect exposure to Rabeprazole Sodium Delayed-Release Tablets in 1064 adult patients exposed for up to 8 weeks. If signs or symptoms consistent with CLE or SLE are noted in patients receiving Rabeprazole Sodium Delayed-Release Tablets, discontinue the drug and refer the patient to the appropriate specialist for evaluation. "B683" is printed on one side with black ink and plain on other side.In adults, symptomatic response to therapy with Rabeprazole Sodium Delayed-Release Tablets does not preclude the presence of gastric malignancy. Serological testing (e.g. Rabeprazole Sodium Delayed-Release Tablets were significantly superior to placebo in producing healing of duodenal ulcers. Effects on maternal bone were observed in pregnant and lactating rats in a pre- and postnatal toxicity study when the PPI was administered at oral doses of 3.4 to 57 times an oral human dose on a body surface area basis. The studies were primarily placebo- and active-controlled trials in adult patients with Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD), Duodenal Ulcers and Gastric Ulcers.

The development and health benefits of breastfeeding should be considered along with the mother's clinical need for Rabeprazole Sodium Delayed-Release Tablets and any potential adverse effects on the breastfed infant from Rabeprazole Sodium Delayed-Release Tablets or from the underlying maternal condition.The safety and effectiveness of Rabeprazole Sodium Delayed-Release Tablets have been established in pediatric patients for adolescent patients 12 years of age and older for the treatment of symptomatic GERD. Get medical help right away if you have: Proton pump inhibitors (such as rabeprazole) may increase your risk for bone Older adults may be more sensitive to the side effects of this drug, especially If someone has overdosed and has serious symptoms such as passing out or If your doctor instructs you to use this medication regularly for a long time, laboratory and medical tests (such as a If you miss a dose, take it as soon as you remember. Significant reductions in daily antacid use were also noted in both Rabeprazole Sodium Delayed-Release Tablets groups compared to placebo at Weeks 2 and 4 (p<0.001).An international randomized, double-blind, active-controlled trial was conducted in 205 patients comparing 20 mg Rabeprazole Sodium Delayed-Release Tablets once daily with 20 mg omeprazole once daily. https://www.webmd.com/drugs/2/drug-17504/rabeprazole-oral/details The recommended dosage of Rabeprazole Sodium Delayed-Release Tablets is 20 mg once daily for 4 weeks.The U.S. multicenter study was a double-blind, parallel-group comparison of Rabeprazole Sodium Delayed-Release Tablets, amoxicillin, and clarithromycin for 3, 7, or 10 days vs. omeprazole, amoxicillin, and clarithromycin for 10 days. Renal impairment: Dose adjustment not necessary. Continue typing to refine. However, the background risk in the U.S. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies. Talk with your doctor.Rabeprazole Sodium Delayed-Release Tablets can cause serious side effects, including:A type of kidney problem (acute interstitial nephritis).What are Rabeprazole Sodium Delayed-Release Tablets?Who should not take Rabeprazole Sodium Delayed-Release Tablets?Do not take Rabeprazole Sodium Delayed-Release Tablets if you:What should I tell my doctor before taking Rabeprazole Sodium Delayed-Release Tablets?Before you take Rabeprazole Sodium Delayed-Release Tablets tell your doctor if you:Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.How should I take Rabeprazole Sodium Delayed-Release Tablets?Do not chew, crush, or split Rabeprazole Sodium Delayed Release TabletsWhat are the possible side effects of Rabeprazole Sodium Delayed-Release Tablets?Rabeprazole Sodium Delayed-Release Tablets may cause serious side effects, including:The most common side effects of Rabeprazole Sodium Delayed-Release Tablets in adults include:The most common side effects of Rabeprazole Sodium Delayed-Release Tablets in adolescents 12 years of age and older include:How should I store Rabeprazole Sodium Delayed-Release Tablets?Keep Rabeprazole Sodium Delayed-Release Tablets and all medicines out of the reach of children.General Information about Rabeprazole Sodium Delayed-Release TabletsWhat are the ingredients in Rabeprazole Sodium Delayed-Release Tablets?We comply with the HONcode standard for trustworthy health information -

PPI associated SLE is usually milder than non-drug induced SLE. Approximately 35% of these treated subjects developed serum gastrin concentrations above the upper limit of normal.Increased serum gastrin secondary to antisecretory agents stimulates proliferation of gastric ECL cells which, over time, may result in ECL cell hyperplasia in rats and mice and gastric carcinoids in rats, especially in females In over 400 patients treated with Rabeprazole Sodium Delayed-Release Tablets (10 or 20 mg) once daily for up to one year, the incidence of ECL cell hyperplasia increased with time and dose, which is consistent with the pharmacological action of the protonpump inhibitor. Consult your Are you considering switching to Rabeprazole SODIUM?Are you planning to see a doctor about switching your medication?Are you planning to see a doctor about switching your medication?Selected from data included with permission and copyrighted by First Databank, Inc. No patient developed the adenomatoid, dysplastic or neoplastic changes of ECL cells in the gastric mucosa.